Additional Listing
Updated : 07:05
21 March 2019
Dechra® Pharmaceuticals PLC
(Dechra or the Company)
Additional Listing
An application for admission to the Premium Segment of the Official List has been made to the Financial Conduct Authority and the London Stock Exchange for an increase of 69,468 ordinary shares of 1 pence each in relation to the existing block listing (the "Shares") for the Company's following schemes:
· Unapproved Share Option Scheme: 26,140
· Approved Share Option Scheme: 8,328
· Long-Term Incentive Scheme: 35,000
These Shares will rank pari passu with the Company's existing shares in issue. It is expected that admission will become effective on 22 March 2019.
For further information, please contact:
Dechra Pharmaceuticals PLC
Melanie Hall, Company Secretary
Telephone number: +44 (0) 1606 814730
Email: corporate.enquiries@dechra.com
About Dechra
Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information, please visit: www.dechra.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.